WO2012118048A1 - 新規マクロライド中間体および新規製造法 - Google Patents
新規マクロライド中間体および新規製造法 Download PDFInfo
- Publication number
- WO2012118048A1 WO2012118048A1 PCT/JP2012/054855 JP2012054855W WO2012118048A1 WO 2012118048 A1 WO2012118048 A1 WO 2012118048A1 JP 2012054855 W JP2012054855 W JP 2012054855W WO 2012118048 A1 WO2012118048 A1 WO 2012118048A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- formula
- disease
- compound
- added
- Prior art date
Links
- 0 CC(C(C(C(OC)O[C@@]([C@@](CC=O)C[C@@](*)[C@](C=C[C@](C(*)C[C@](N)OC(C[C@]1*)=[*+])N(C)CCCc2ccnc3c2cccc3)O)[C@]1O)O)N(C)C)O Chemical compound CC(C(C(C(OC)O[C@@]([C@@](CC=O)C[C@@](*)[C@](C=C[C@](C(*)C[C@](N)OC(C[C@]1*)=[*+])N(C)CCCc2ccnc3c2cccc3)O)[C@]1O)O)N(C)C)O 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to a novel process for producing a macrolide derivative that is effective as a therapeutic agent for bacterial infections in animals.
- the present inventors manufacture these derivatives according to the following method. That is, (A) after selectively epoxidizing the olefin sites at positions 12 and 13 of the protected body modified with an appropriate protecting group, (B) the epoxy site was cleaved with azide, and (C) was generated. The amino alcohol obtained by reducing the azide is obtained by (D) Borch reductive amination reaction (Borch, R. F.et al. J. Org. Chem, (1972), 37, 1673.) The compound is introduced into the compound through a series of steps of introducing a side chain to be removed and (E) finally performing deprotection.
- An object of the present invention is to provide a novel intermediate and a bacterial respiratory infection for the animal described above including the compound represented by the formula (III) in a simple and high yield by way of the intermediate.
- An object of the present invention is to provide a novel process for producing such a compound.
- the present invention provides a method for producing Formula (III) simply and in good yield while suppressing the by-product generated in the production process, and a monoalkyl compound (I) that is an important intermediate for suppressing the by-product. It is to be.
- the present inventors have solved the above problem by avoiding reductive alkylation from an amino group that has caused a decrease in yield. That is, by reducing an azide obtained by ring-opening an epoxide, an aza wittig type intermediate formed directly by an azide group and a phosphine, the desired monoalkylamino intermediate ( I) to get.
- the target product can be obtained by using the minimum amount of aldehyde corresponding to the desired side chain used in the subsequent Borch reduction. Made it possible to obtain.
- the amount of reagents was reduced, the yield was improved, and purification was facilitated, and the present invention was completed as an efficient new production method.
- the present invention provides a method for efficiently producing Formula (III) exhibiting excellent antibacterial activity against bacterial infections of animals, and novel intermediates (I) and (II).
- the monoalkylated amino compound (I) obtained by the production method according to the present invention is a very useful synthetic intermediate. Specifically, the amount of the aldehyde corresponding to the side chain to be added can be suppressed to almost the theoretical equivalent by passing through the monomethylated amino compound (II). III) It became possible to provide manufacturing methods.
- the formula (III) provided by this production method is effective against gram-positive bacteria, mycoplasma, chlamydia, rickettsia as well as ordinary macrolides, and is particularly problematic for animal infections. It is effective against gram-negative bacteria.
- the compound manufactured by this invention can show the antimicrobial effect excellent in the causative microbe with respect to respiratory tract infection of animals, such as a cow and a pig.
- the present inventors have succeeded in producing a compound represented by the formula (I) or a salt thereof for the first time, and further through this formula (I), an excellent antibacterial agent for animals represented by the formula (III).
- a novel production method capable of producing the compound with high yield could be found.
- the present invention provides (1) a compound represented by the following formula (I) or a pharmacologically acceptable salt, (I) (In the formula, R represents a lower alkyl group, an alkyl group which may have a substituent, an aralkyl group which may have a substituent, a heterocyclic alkyl group which may have a substituent, R 1 represents a methyl group or an ethyl group, and R 2 represents an ethyl group or an isobutyl group.) (2) a compound represented by the following formula (II) or a pharmacologically acceptable salt, (II) (In the formula, R 1 represents a methyl group or an ethyl group, and R 2 represents an ethyl group or an isobutyl group.) (3) The compound according to (2), wherein R 1 and R 2 represent an ethyl group, (4) R 1 represents a methyl group, and R 2 represents an isobutyl group.
- the “lower alkyl group” represents an alkyl group having 1 to 6 carbon atoms.
- the alkyl group may be chain, branched or cyclic.
- C 1-6 alkyl groups such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl and the like, and C 3-6 cycloalkyl such as cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl Groups and the like.
- an alkyl group which may have a substituent, an aralkyl group which may have a substituent, and a heterocyclic alkyl group which may have a substituent specifically, Phenylalkyl group optionally having substituent, naphthylalkyl group optionally having substituent, quinolinylalkyl group optionally having substituent, isoquinoline optionally having substituent
- Yl alkyl group, and the like may naphthyridine-yl alkyl group optionally having a substituent.
- examples of the “organophosphorus reagent” include triphenylphosphine, trimethylphosphine, triethylphosphine, tributylphosphine, and the like.
- Formula (III) produced in the present invention includes, for example, the following bacterial causative bacteria, bacterial causative bacteria of swine disease, Bacillus anthracis, Brucella suis, and Clostridium chauvoei , Leptospira, Salmonella serovar Dublin, S. Enteritidis, S. Typhimurium, S. Choleraesuis, Francisella tularensis, F. holarctia, F. mediasiatica, F. novicida, ), Brachyspira hyodysenteriae, Staphylococcus hyicus, Lawsonia intracellularis, verotoxin-producing E.
- VTEC Actinobacillus equuli, A.Apleuropneumoniae, A. susi, Arcanobacteriumanopyogenes, Clostridium perfringensum Escherichia coli (ETEC), intestinal adhesion microvilli extinction Escherichia coli (AEEC), Pasteurella multocida B type Type E, Mycoplasma hyopneumoniae, Streptococcus suis, Haemophilus parasuis, Bacillus bacterium anthracis, Brucella abortus, B. acanis, Mycobacterium bovis, Yone bacterium (Mycobacterium avium subsp.
- Emphysema (Clostridium chauvoei), tetanus (Clostridium tetani), Leptospira, Salmonella serovar Dublin, S. Enteritidis, S. Typhimurium, S. Choleraesuis, Campylobacter fetus subsp. Venere , C. sordellii, C. perfringens (type A), C. novyi (type A), Actinobacillus lignieresii, Clostridium perfringens, Corynebacterium renale, C. pilosum, C. cystitidis, enterotoxigenic E.
- ETEC verotoxin producing Escherichia coli
- VTEC verotoxin producing Escherichia coli
- AEEC intestinal adhesion microvilli extinction E. coli
- Pasteurellaurmultocida Mannheimia haemolytica
- P. trehalosi Mycoplasma mycoides subsp. Mycoid es SC type
- Clostridium botulinum C type D toxin-producing bacteria, Mycoplasma bovis, M. bovigenitalium, M. dispar, Ureaplasma diversum, Mycoplasma alkalescens, M. bovigenitalium, M. bovigenitalium, M bo , M. californicum, M.
- Salmonella Gallinarum (Salmonella enterica subsp. Enterica serovar Gallinarum biovar Gallinarum), S. enterica, S. Typhimurium, S. Avibacterium, Haemophilus fr Staphylococcus aureus, S. hyicus, Clostridium botulinum type C poison It is effective for production of bacteria and the like.
- the formula (III) produced in the present invention is effective against, for example, the following bacterial diseases which are particularly problematic in animal infections.
- bacterial diseases which are particularly problematic in animal infections.
- swine swine charcoal, swine brucellosis, swine emphysema, swine leptospirosis, swine Weil disease, swine salmonellosis, swine mania, swine atrophic rhinitis, swine erysipelas, swollen exudative dermatitis (exudative dermatitis, soot) Disease), swine proliferative enteritis, swine edema disease, swine actinobacillus, swine alkanobacterium pyogenes infection, swine necrotizing enteritis, swine pleural pneumonia, swine mycobacterial disease, swine colitis,
- equine disease effective for equine nose, equine nasal polyposis, equine tetanus, equine paratyphoid, equine Klebsiella infection, equine infectious uteritis, Rhodococcus equi infection, equine disease, equine chlamydial infection, equine potomac fever It is.
- sheep goat disease, Brucella disease, sheep dysentery, pseudotuberculosis, non-suppurative polyarthritis, lamb porcine erysipelas, lamb clostridiasis, lamb infectious gonorrhea dermatitis, bark disease, water heartworm Infectious ophthalmitis, epidemic sheep miscarriage, sheep sheep polyarthritis, infectious serositis, infectious aspiration, goat infectious pleural pneumonia etc.
- Dog cat, canine leptospirosis, canine lyme disease, canine brucellosis, canine campylobacterosis, canine bordeterosis, canine cat anaerobic bacteriosis, cat leptospirosis, cat tuberculosis disease, canine aelicchia disease, salmon poisoning, cat scratch disease, It is feline haemobartonellosis, feline chlamydial infection, and canine mycoplasma disease.
- the monoalkylation in this step is a desired side chain. For example, there is no problem even if a method of methylation after introducing a 3- (quinolin-4-yl) propyl group is employed. However, since monomethylation is first performed, the reaction can be completed with the necessary amount (1-1.5 equivalents) of the reagent for the subsequent side chain introduction, which is extremely efficient. Therefore, a production method for carrying out, for example, 3- (quinolin-4-yl) propylation via a monomethylated amino form is described here.
- alkylation of the amino group carried out after monomethylation is not limited to 3- (quinolin-4-yl) propyl, and an aldehyde according to the purpose can be appropriately selected and used.
- aldehyde reagent used in the monoalkylation reaction for example, paraformaldehyde, acetaldehyde, propionaldehyde or the like may be used for the purpose of lower alkylation such as methyl group, ethyl group, and butyl group, and 3- (quinoline- Introduction of an optionally substituted alkyl group, an optionally substituted aralkyl group, an optionally substituted heterocyclic alkyl group, etc., such as 4-yl) propyl group If the alkylation is to be carried out, the corresponding aldehyde may be used.
- aldehyde reagent in the present specification includes, for example, paraformaldehyde, acetaldehyde, propionaldehyde, benzaldehyde, 2-phenylethylaldehyde, 3-phenylpropylaldehyde, cinnamylaldehyde, 4-phenylbutylbutyraldehyde, 5-phenylpentyl.
- paraformaldehyde is preferable, and it may be added after confirming an active intermediate (disappearance of raw materials) formed with phosphine described later.
- the solvent used in this reaction may be chloroform, methylene chloride or the like, and the organic phosphorus reagent used may be trimethylphosphine, triphenylphosphine, triethylphosphine, tributylphosphine or the like. It is preferable to use 1 to 3 equivalents of trimethylphosphine.
- This reaction proceeds with good yield in the range of 0 ° C. to 80 ° C., and the reaction time is 1 hour to 36 hours. After confirming disappearance of the raw material, 2 to 10 equivalents of paraformaldehyde was added. The reaction is in the range of 0 ° C. to 80 ° C., and the reaction time is 1 hour to 36 hours.
- a lower alcohol such as methanol or ethanol in which 1 to 5 equivalents of sodium borohydride is dissolved may be added to the above reaction solution.
- the temperature proceeds in the range of 0 ° C. to 50 ° C. with good yield, and the reaction time is 5 minutes to 1 hour.
- picoline borane, pyridine borane and the like can be used in addition to sodium borohydride, but sodium borohydride is preferable.
- Both formula (I) and formula (II) may take the form of a salt.
- Preferred salts are pharmacologically acceptable salts.
- representative acid addition salts include hydrochlorides, sulfates, nitrates, hydrobromides, hydroiodides, phosphates and other inorganic acid salts, acetates, trifluoroacetates, lactates , Citrate, oxalate, succinate, glutarate, malate, tartrate, fumarate, mandelate, maleate, benzoate, nicotinate, phthalate, etc.
- Organic sulfonic acid such as carboxylate, methanesulfonate, ethanesulfonate, 2-hydroxyethanesulfonate, benzenesulfonate, p-toluenesulfonate, 2-naphthalenesulfonate, camphorsulfonate
- acidic amino acid salts such as salts, aspartate and glutamate.
- inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid and phosphoric acid
- organic acids such as oxalic acid, maleic acid, methanesulfonic acid, p-toluenesulfonic acid and citric acid. Salt. More preferred are salts with hydrochloric acid, hydrobromic acid, sulfuric acid and methanesulfonic acid.
- the compound formulas (I) and (II) of the present invention can also be used as solvate forms.
- examples include, but are not limited to, water, methanol, ethanol, ethylene glycol, propylene glycol, ethyl acetate, and butyl acetate.
- Solvents for the solvate preferably include water, ethanol and ethyl acetate.
- the acetic acid to be added is used in an amount of 1 to 5 equivalents, and the reducing agent in the Borch reductive amination reaction may be sodium acetoxyborohydride, picoline borane, etc. in addition to sodium cyanoborohydride. Preferably, sodium cyanoborohydride etc. are mentioned.
- the amount used is preferably 1 to 5 equivalents, the temperature proceeds in a yield range of 0 ° C. to 50 ° C., and the reaction time is 5 minutes to 24 hours.
- the aldehyde reagent used in the second step is synonymous with the aldehyde reagent.
- the 18-position protecting group and neutral sugar are removed by reaction with difluoroacetic acid in a mixed solvent of acetonitrile and water, thereby removing the formula (V III), specifically, formula (IIIa) or formula (IIIb) was obtained.
- a solvent used in this reaction an equivalent mixed solution of acetonitrile and water is preferably used in an amount of 10 times (g / ml) to 300 times (g / ml).
- difluoroacetic acid monofluoroacetic acid, trifluoroacetic acid, acetic acid and the like may be used, and 1 to 30 equivalents are preferably used.
- the reaction proceeds with good yield in the range of 20 ° C. to 50 ° C., and the reaction time is 12 hours to 4 days.
- the organic layer was washed successively with 50 ml of saturated aqueous sodium bicarbonate and 50 ml of saturated brine, and the organic layer was dried over anhydrous sodium sulfate and filtered.
- the residue obtained by concentrating the filtrate under reduced pressure was purified by silica gel column chromatography (chloroform-methanol-aqueous ammonia 200: 10: 1)) to obtain 654 mg of the title compound.
- Example 2 9-O-acetyl-4'-demycarosyl-12,13-dihydro-13-hydroxy-12- (N-methyl-N- (3- (quinolin-4-yl) propyl) aminomidicamycin (formula (IIIa)
- Acetonitrile (1 ml) was dissolved in 60 mg of the compound of Example 1, and 1 ml of water was added, and 70 ⁇ l of difluoroacetic acid was added and stirred at 40 ° C. for 60 hours.
- Example 3 9-O-Acetyl-12-azido-12,13-dihydro-13-hydroxyjosamycin 18-dimethylacetal (compound represented by formula (IVb)) 1.0 g of josamycin was dissolved in 15 ⁇ l of methylene chloride. After adding 178 ⁇ l of pyridine, 114 ⁇ l of acetyl chloride was gradually added dropwise. After stirring at room temperature for 3 hours, saturated aqueous sodium hydrogen carbonate was added. Methylene chloride (35 ml) was added, and the mixture was washed successively with saturated aqueous sodium hydrogen carbonate and saturated brine. The organic layer was dried over anhydrous sodium sulfate and filtered.
- the reaction product obtained by concentrating the filtrate under reduced pressure was dissolved by adding 12 ml of chloroform, and 982 mg of 3-chloroperbenzoic acid was added and reacted at room temperature for 14 hours. 50 ml of ethanol was added to the reaction solution, and 18 ml of 5% aqueous sodium dithionite aqueous solution was slowly added dropwise under ice cooling. After stirring for 1 hour, the mixture was concentrated under reduced pressure, saturated aqueous sodium hydrogen carbonate was added, and the mixture was extracted twice with 50 ml of chloroform.
- Example 5 9-O-acetyl-4'-demycarosyl-12,13-dihydro-13-hydroxy-12- (N-methyl-N- (3- (quinolin-4-yl) propyl) aminojosamycin (in formula (IIIb) 1 mg of acetonitrile was dissolved in 66 mg of the compound of Example 4, and 1 ml of water was added, and 73 ⁇ l of difluoroacetic acid was added and stirred for 60 hours at 40 ° C. The reaction solution was saturated.
- the in vitro antibacterial activity of the compound obtained by the present invention is determined by the CLSI method (former NCCLS method, M31-A2) (Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated from Animals; Approved Standard -Second Edition NCCLS M31-A2 Vol.22 No.6 2002), measured using a micro liquid dilution method.
- CLSI method former NCCLS method, M31-A2
- the medium composition used for the measurement is shown below.
- Minimum inhibitory concentration After incubation in the presence of 5% carbon dioxide at 37 ° C for 20-24 hours, the presence or absence of growth of the test strain is observed with the naked eye, and the minimum drug concentration that completely inhibits the growth of the test strain is the minimum inhibitory concentration (Minimum inhibitory concentration;).
- Liquid medium BBL Mueller Hinton II broth (Japan Becton Dickinson) 22.0 g Horse hemolysis * 20 mL NAD (Wako Pure Chemical Industries) 0.2 g Purified water 1000 mL * Horse hemolyzed saponin (Kanto Chemical) 2.0 g Purified water 10 mL Horse defibrillation blood (Japan Lamb) 100 mL Saponin was dissolved in purified water, sterilized, and added to horse defibrillated blood.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
Description
(式中、Rは低級アルキル基、置換基を有していてもよいアルキル基、置換基を有していてもよいアラルキル基、置換基を有していてもよい複素環アルキル基を表し、R1は、メチル基またはエチル基を表し、R2は、エチル基またはイソブチル基を表す。)
(2)下記式(II)で表される化合物または薬理学的に許容される塩、
(式中、R1は、メチル基またはエチル基を表し、R2は、エチル基またはイソブチル基を表す。)
(3)R1とR2がエチル基を表す(2)に記載の化合物、
(4)R1はメチル基を、R2がイソブチル基を表す(2)に記載の化合物などに関する。
(式中、R1は、メチル基またはエチル基を表す。)
(6)式(IV)と有機リン試薬とを反応させた後、アルデヒド試薬と反応させ、さらに還元反応に付すことを特徴とする(1)記載の式(I)の製造方法、
(式中、R1は、メチル基またはエチル基を表し、R2は、エチル基またはイソブチル基を表す。)
(7)式(IV)と有機リン試薬とを反応させた後、パラホルムアルデヒドと反応させ、さらに還元反応に付すことを特徴とする請求項2から4のいずれか一項に記載の式(II)の製造方法に関するものである。
9-O-アセチル-12-アジド-12,13-ジヒドロ-13-ヒドロキシミデカマイシン 18-ジメチルアセタール(国際公開第2002/064607中の実施例3:(IVa))、あるいは9-O-アセチル-12-アジド-1 2,13-ジヒドロ-13-ヒドロキシジョサマイシン 18-ジメチルアセタール(IVb)に対して、有機リン試薬を加えて、原料の消失を確認した後に、所望とするアルデヒド試薬を加える。数時間反応させて単離不能な中間体を構築し、それを還元することで目的とするモノアルキル化アミノ体(I)を得た。
上記反応で得られたモノメチルアミノ体(II)(Rがメチル基を表す式(I))に対して、酢酸存在下、3-(キノリン-4-イル)プロピルアルデヒドを加え、ナトリウムシアノボロヒドリドによるBorch還元的アミノ化反応により目的化合物(V)を得た。本反応に用いるアルデヒド試薬は、1~1.5当量でよく、溶媒はメタノール、エタノール等の低級アルコールの他、アセトニトリル、塩化メチレンを使用することも可能である。
アミノ基を修飾した上記化合物(V)に対して、アセトニトリルと水との混合溶媒中でジフルオロ酢酸との反応により、18位の保護基および中性糖を除去することで、式(III)、具体的には式(IIIa)あるいは式(IIIb)を得た。本反応で用いる溶媒としては、アセトニトリル及び水の等量混合溶液を、10倍量(g / ml)~300倍量(g / ml)用いるとよい。また、ジフルオロ酢酸の他、モノフルオロ酢酸、トリフルオロ酢酸、酢酸等でもよく、1~30当量用いるとよい。反応は20℃~50℃の範囲で収率良く進行し、反応時間は12時間~4日間である。
9-O-アセチル-12,13-ジヒドロ-13-ヒドロキシ-12-( N-メチル-N-(3-(キノリン-4-イル)プロピル)アミノミデカマイシン 18-ジメチルアセタール((Va);R1=R2=エチル基で表される式(V)化合物)の製造法
特許記載(国際公開第2002/064607中の実施例3)の方法に従って得られる化合物である9-O-アセチル-12-アジド-12,13-ジヒドロ-13-ヒドロキシミデカマイシン 18-ジメチルアセタール961 mgにクロロホルム 24 ml を加え溶解し、トリメチルホスフィンの1Mトルエン溶液2 mlを加え、室温で1時間攪拌した。パラホルムアルデヒド150 mgを加えて、さらに5時間攪拌した後、ナトリウムボロヒドリド189 mgをメタノール1mlに溶解して徐々に加えた。室温で30分間攪拌した後、減圧濃縮し、得られた残さをシリカゲルカラムクロマトグラフィー(クロロホルム-メタノール-アンモニア水(200:10:1))で精製して、化合物(IIa)を630 mg得た。
(1) マススペクトル (ESI) : m/z 949(M+H)+
(2) 1H NMRスペクトル (400MHz, CDCl3) δ(ppm) : 0.98(d, 3H), 1.12(s, 3H),1.12(d, 3H), 1.14(t, 3H), 1.18(t, 3H), 1.28(d, 3H), 1.31(d, 3H), 1.40-1.80(m, 5H), 1.85(dd, 1H), 2.07(s, 3H), 2.18(d, 2H), 2.30-2.55(m, 10H), 2.43(s, 3H), 2.51(s, 6H), 2.74(dd, 1H), 2.86(dd, 1H), 3.20(s, 3H), 3.28(s, 3H), 3.45(br d, 3H), 3.53 (s, 3H), 3.58 (dd, 1H), 4.02(br s, 1H), 4.47(dq, 1H), 4.52(m, 1H), 4.63(t, 1H), 4.68(d, 1H), 5.08(d, 1H), 5.18(br d, 1H), 5.35(dd, 9-H), 5.73(dd, 1H), 5.95(dd, 1H).
(1) マススペクトル (FAB) : m/ z 1118 (M+H)+
(2) 1H NMRスペクトル (300MHz, CDCl3 δ(ppm) : 0.92(d, 3H), 1.06(t, 3H), 1.11(s, 3H), 1.17(t, 3H), 1.28(d, 1H), 1.28(d, 1H), 1.51(br t, 1H), 1.51(br dd, 1H), 1.83(dd, 1H), 2.02(d, 1H), 2.05(s, 3H), 2.35(s, 3H), 2.51(s, 6H), 2.65(m, 2H), 2.74(dd, 1H), 3.17(s, 3H), 3.27(s, 3H), 3.32(m, 1H), 3.32(m, 1H), 3.43(br d, 1H), 3.53(s, 3H), 3.59(dd, 1H), 3.98(br d, 1H), 3.98(br dd, 1H), 4.48(dq, 1H), 4.54(d, 1H), 4.58(t, 1H), 4.61(d, 1H), 5.00(ddq, 1H), 5.07(d, 1H), 5.16(br dd, 1H), 5.38(br s, 1H), 5.72(br d, 1 H), 5.81(br d, 1H), 7.24(d, 1H), 7.56(ddd, 1H), 7.69(ddd, 1H), 8.03(br d, 1H), 8.09(br d, 1H) , 8.78 (d, 1H).
9-O-アセチル-4 ’-デマイカロシル-12,13-ジヒドロ-13-ヒドロキシ-12-( N-メチル-N-(3-(キノリン-4-イル)プロピル)アミノミデカマイシン(式(IIIa)で表される化合物)の製造法
実施例1の化合物 60 mg にアセトニトリル1 ml を加え溶解し、水1 ml を加えた。ジフルオル酢酸 70 μlを加えて40℃で60時間攪拌した。反応液に飽和重曹水20 ml を加え、酢酸エチル40 ml で抽出した。有機層を飽和重曹水20 ml、飽和食塩水20 ml で順次洗浄し、有機層を無水硫酸ナトリウムで乾燥後、これを濾過した。濾液を減圧濃縮して得られた残さを分取用TLC(クロロホルム-メタノール-アンモニア水(100:10:1))で精製して、表記化合物を24 mg 得た。
(1) マススペクトル (FAB) : m/z 872 (M+H)+
(2) 1H NMRスペクトル (300MHz, CDCl3 δ(ppm) : 0.88(d, 3H), 1.05(br t, 3H), 1.12(t, 3H), 1.21(d, 3H), 1.22(d, 3H), 1.50(dt, 3H), 1.55(br dd, 1H), 2.02(m, 2H), 2.04(s, 3H), 2.32(s, 3H), 2.34(t, 1H), 2.50(s, 6H), 2.99(dd, 1H), 3.06(t, 1H), 3.27(dq, 1H), 3.39(br d, 1H), 3.48(dd, 1H), 3.54(s, 3H), 3.97(br d, 1H), 4.02(br dd, 1H), 4.45(d, 1H), 5.00(ddq, 1H), 5.17(br s, 1H), 5.26(br t, 1H), 5.76(dd, 1H), 5.82(br d, 1H), 7.23(d, 1H), 7.54(dd, 1H), 7.68(dd, 1H), 8.04(d, 1H), 8.09(d, 1H) , 8.78 (d, 1 H), 9.67(s, 1H).
9-O-アセチル-12-アジド-12,13-ジヒドロ-13-ヒドロキシジョサマイシン 18-ジメチルアセタール(式(IVb)で表される化合物)の製造法
ジョサマイシン1.0 g を塩化メチレン15 μlに溶解してピリジン178 μl を加えた後、アセチルクロリド114 μl を徐々に滴下した。室温で3時間攪拌した後、飽和重曹水を加えた。塩化メチレン35 ml を加え、飽和重曹水および飽和食塩水で順次洗浄した。有機層を無水硫酸ナトリウムで乾燥後、これを濾過した。濾液を減圧留去して得られた濃縮物をメタノール3 ml を加え溶解し、オルト蟻酸メチル3 ml 及びPPTS 322 mg を加え、50℃で33時間攪拌した。反応液に飽和重曹水を加え減圧濃縮し、クロロホルム50 ml で2回抽出した。有機層を飽和重曹水および飽和食塩水で順次洗浄した。有機層を無水硫酸ナトリウムで乾燥後、これを濾過した。
(1) マススペクトル (ESI) : m/z 974 (M+H)+
(2) 1H NMRスペクトル (400MHz, CDCl3 δ(ppm) : 0.94(d, 3-H), 0.96(d, 3-H), 1.12(s, 3H), 1.13(d, 3H), 1.30(d, 3H), 1.50-1.90(m, 3H), 2.04(s, 3H), 2.10(s, 3H), 2.50(br s, 6H), 2.61(dd, 1-H), 2.85(dd, 1H), 3.16(s, 3H), 3.27(s, 3H), 3.53 (s, 3H), 3.57(dd, 2’-H), 3.93(br dd, 1H), 4.00(br d, 1H), 4.25(br s, 1H), 4.40-4.65(m, 4H), 5.05-5.15(m, 3H), 5.32(br s, 1H), 5.78(br s, 2H).
9-O-アセチル-12,13-ジヒドロ-13-ヒドロキシ-12-( N-メチル-N-(3-(キノリン-4-イル)プロピル)アミノジョサマイシン 18-ジメチルアセタール((Vb);R1=メチル基、R2=イソブチル基で表される式(V)化合物)の製造法
実施例3の化合物500 mgにクロロホルム 12 ml を加え溶解し、トリメチルホスフィンの1Mトルエン溶液1 mlを加え、室温で1時間攪拌した。パラホルムアルデヒド80 mgを加えて、さらに5時間攪拌した後、ナトリウムボロヒドリド100 mgをメタノール500μlに溶解して徐々に加えた。室温で30分間攪拌した後、減圧濃縮し、得られた残さをシリカゲルカラムクロマトグラフィー(クロロホルム-メタノール-アンモニア水(200:10:1))で精製して、化合物(IIb)を315 mg得た。
(1) マススペクトル (ESI) : m/z 963(M+H)+
(2) 1H NMRスペクトル (400MHz, CDCl3) δ(ppm) : 0.96(d, 3H), 1.10(s, 3H),1.12(d, 3H), 1.20-130(m, 6H), 1.40-1.80(m, 5H), 2.03(s, 3H), 2.10(s, 3H), 2.28(d, 2H), 2.43(s, 3H), 2.49(s, 6H), 2.66(dd, 1H), 2.80(dd, 1H), 3.23(s, 3H), 3.28(s, 3H), 3.52 (s, 3H), 3.56(dd, 1H), 3.86(br s, 1H), 4.00(br d, 1H), 4.45 (dq, 1H), 4.52(d, 1H), 4.60(d, 1H), 5.0 7(d, 1H), 5.15(m, 2H), 5.31(dd, 9-H), 5.65(dd, 1H), 5.80(dd, 1H).
(1) マススペクトル (ESI) : m/z 1,132 (M+H)+
(2) 1H NMRスペクトル (400MHz, CDCl3 δ(pp m) : 0.92(d, 3H), 0.95(d, 3H), 1.11(s, 3H), 1.12(d, 3H), 1.15(d, 3H), 1.26(d, 3H), 2.03(s, 3H), 2.05(s, 3H), 2.22(s, 3H), 2.27(d, 1H), 2.50(s, 6H), 2.65(m, 2H), 3.15(s, 3H), 3.27(s, 3H), 3.53(s, 3H), 3.57(dd, 1H), 3.96(m, 2H), 4.50(m, 3H), 4.60(d, 1H), 5.00(m, 1H), 5.06(d, 1H), 5.15(br s, 1H), 5.37(br s, 1H), 5.72(br dd, 1H), 5.81(br d, 1H), 7.23(d, 1H), 7.55(dd, 1H), 7.68(dd, 1H), 8.02(d, 1H), 8.08(d, 1H) , 8.78 (d, 1H).
9-O-アセチル-4 ’-デマイカロシル-12,13-ジヒドロ-13-ヒドロキシ-12-( N-メチル-N-(3-(キノリン-4-イル)プロピル)アミノジョサマイシン(式(IIIb)で表される化合物)の製造法
実施例4の化合物66 mg にアセトニトリル1 ml を加え溶解し、水1 ml を加えた。ジフルオル酢酸 73 μl を加えて40℃で60時間攪拌した。反応液に飽和重曹水20 ml を加え、酢酸エチル40 ml で抽出した。有機層を飽和重曹水20 ml、飽和食塩水20 ml で順次洗浄し、有機層を無水硫酸ナトリウムで乾燥後、これを濾過した。濾液を減圧濃縮して得られた残さを分取用TLC(クロロホルム-メタノール-アンモニア水(100:10:1))で精製して、表記化合物を28 mg 得た。
(1) マススペクトル (ESI) : m/z 858(M+H)+
(2) 1H NMRスペクトル (400MHz, CDCl3 δ(ppm) : 0.88(d, 3H), 1.18(d, 3H), 1.21(d, 3H), 1.53(m, 2H), 2.05(s, 3H), 2.24(s, 3H), 2.33(dd, 1H), 2.50(s, 6H), 3.05(m, 2H), 3.18(br t, 1H), 3.26(dq, 1H), 3.36(br d, 1H), 3.46(dd, 1H), 3.53(s, 3H), 3.97(m, 2H), 4.45(d, 1H), 5.00(ddq, 1H), 5.15(br s, 1H), 5.23(br t, 1H), 5.75(dd, 1H), 5.84(br d, 1H), 7.23(d, 1H), 7.54(dd, 1H), 7.68(dd, 1H),8.02(d, 1H), 8.08(d, 1H) , 8.78 (d, 1H), 9.67(s, 1H).
本発明で得られる化合物のin vitro抗菌活性をCLSI法(旧NCCLS法、M31-A2)(Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated from Animals; Approved Standard-Second Edition NCCLS M31-A2 Vol.22 No.6 2002)に準じ、微量液体希釈法を用いて測定した。測定に使用した培地組成を下記に示した。
BBL Mueller Hinton II broth (日本ベクトン・ディッキンソン) 22.0 g
馬溶血液* 20 mL
NAD(和光純薬) 0.2 g
精製水 1000 mL
*馬溶血液
サポニン(関東化学) 2.0 g
精製水 10 mL
馬脱繊血(ジャパン・ラム) 100 mL
精製水でサポニンを溶解し、滅菌後、馬脱繊血に添加した。
Claims (7)
- R1とR2がエチル基を表す請求項2に記載の化合物。
- R1はメチル基を、R2がイソブチル基を表す請求項2に記載の化合物。
- 式(IV)と有機リン試薬とを反応させた後、パラホルムアルデヒドと反応させ、さらに還元反応に付すことを特徴とする請求項2から4のいずれか一項に記載の式(II)の製造方法。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12752556.6A EP2682399A4 (en) | 2011-02-28 | 2012-02-28 | NEW MACROLIDE INTERMEDIATE AND NEW PRODUCTION PROCESS |
CN2012800106541A CN103391944A (zh) | 2011-02-28 | 2012-02-28 | 一种新大环内酯中间体和新的制备方法 |
US14/001,014 US20140039171A1 (en) | 2011-02-28 | 2012-02-28 | Novel macrolide intermediate and novel production process |
JP2013502353A JPWO2012118048A1 (ja) | 2011-02-28 | 2012-02-28 | 新規マクロライド中間体および新規製造法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011043150 | 2011-02-28 | ||
JP2011-043150 | 2011-02-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012118048A1 true WO2012118048A1 (ja) | 2012-09-07 |
Family
ID=46757980
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2012/054855 WO2012118048A1 (ja) | 2011-02-28 | 2012-02-28 | 新規マクロライド中間体および新規製造法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20140039171A1 (ja) |
EP (1) | EP2682399A4 (ja) |
JP (1) | JPWO2012118048A1 (ja) |
CN (1) | CN103391944A (ja) |
WO (1) | WO2012118048A1 (ja) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002064607A1 (fr) | 2001-02-14 | 2002-08-22 | Meiji Seika Kaisha, Ltd. | Nouveaux derives de macrolides a 16 elements modifies en 12 et 13 |
WO2006073172A1 (ja) * | 2005-01-07 | 2006-07-13 | Meiji Seika Kaisha, Ltd. | 12-オキシ-13-アミノ含有16員環マクロライド誘導体及びその製造法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2671887A4 (en) * | 2011-01-31 | 2014-06-25 | Meiji Seika Pharma Co Ltd | NEW MACROLIDE DERIVATIVE |
-
2012
- 2012-02-28 WO PCT/JP2012/054855 patent/WO2012118048A1/ja active Application Filing
- 2012-02-28 EP EP12752556.6A patent/EP2682399A4/en not_active Withdrawn
- 2012-02-28 JP JP2013502353A patent/JPWO2012118048A1/ja active Pending
- 2012-02-28 US US14/001,014 patent/US20140039171A1/en not_active Abandoned
- 2012-02-28 CN CN2012800106541A patent/CN103391944A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002064607A1 (fr) | 2001-02-14 | 2002-08-22 | Meiji Seika Kaisha, Ltd. | Nouveaux derives de macrolides a 16 elements modifies en 12 et 13 |
WO2006073172A1 (ja) * | 2005-01-07 | 2006-07-13 | Meiji Seika Kaisha, Ltd. | 12-オキシ-13-アミノ含有16員環マクロライド誘導体及びその製造法 |
Non-Patent Citations (4)
Title |
---|
"NCCLS M31-A2", vol. 22, 2002, article "Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated from Animals" |
BORCH, R. F. ET AL., J. ORG. CHEM, vol. 37, 1972, pages 1673 |
MIURA TOMOAKI ET AL.: "Novel 16-membered macrolides modified at C-12 and C-13 positions of midecamycin Al and miokamycin. Part 1: Synthesis and evaluation of 12,13-carbamate and 12-arylalkylamino-13- hydroxy analogues", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 16, no. 7, 2008, pages 3985 - 4002, XP022593507 * |
See also references of EP2682399A4 * |
Also Published As
Publication number | Publication date |
---|---|
EP2682399A1 (en) | 2014-01-08 |
US20140039171A1 (en) | 2014-02-06 |
JPWO2012118048A1 (ja) | 2014-07-07 |
EP2682399A4 (en) | 2014-08-06 |
CN103391944A (zh) | 2013-11-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH11315093A (ja) | 3,6―ケタ―ル及びエノ―ルエ―テルマクロライド抗生物質 | |
JP3842973B2 (ja) | 13員アザリド類および抗生物質としてのそれらの使用 | |
AU1675400A (en) | Ketolide antibiotics | |
HRP20010306A2 (en) | Novel macrolide antibiotics | |
US20190211003A1 (en) | Novel 16-member triamilide derivatives and uses thereof | |
KR20160014656A (ko) | 틸로신 유도체 및 그의 제조 방법 | |
WO2012105562A1 (ja) | 新規マクロライド誘導体 | |
WO2012118048A1 (ja) | 新規マクロライド中間体および新規製造法 | |
CN110590885A (zh) | 20-取代-5-o-碳霉胺糖基-泰乐内酯衍生物 | |
HRP980248A2 (en) | Erythromycin derivatives | |
EP2669288A1 (en) | New monosaccharide derivatives and biological applications thereof | |
EP1115732B1 (en) | Carbamate and carbazate ketolide antibiotics | |
WO1999062920A1 (en) | Tricyclic 3-keto derivatives of 6-o-methylerythromycin | |
CN108864228B (zh) | 十六元环三胺内酯衍生物及其应用 | |
US6482801B2 (en) | 9a, 11b-dehydro derivatives of 9-oxime-3-keto-6-O- methylerythromycin | |
US6492342B1 (en) | Hygromycin A prodrugs | |
WO2012105563A1 (ja) | マクロライド誘導体からなる動物用医薬品 | |
EP1749832A2 (en) | Carbamate and carbazate ketolide antibiotics | |
EP1298138A1 (en) | Carbamate and Carbazate Ketolide Antibiotics |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12752556 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2013502353 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012752556 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14001014 Country of ref document: US |